Loading
Life sciences · Journal article
Advanced Healthcare Materials · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Chemotherapeutic agents are often limited by poor tumor‐specific accumulation, leading to off‐target toxicity, while monochemotherapy frequently results in multidrug resistance and suboptimal treatment outcomes. To address these challenges, we have developed a carbon dot‐based nanogel drug delivery system that integrates both glutathione (GSH) and photothermal dual‐responsiveness, enabling controlled drug release, active tumor targeting, and synergistic photothermal‐chemotherapy. Specifically, phenylboronic acid functionalized on the nanogel surface confers tumor‐targeting capability. Upon internalization into tumor cells with elevated GSH levels, the nanogel disintegrates, releasing carbon dots conjugated with the chemotherapeutic drug doxorubicin (DOX). Under near‐infrared (NIR) irradiation, the carbon dots generate heat, which not only directly damages cancer cells but also triggers on‐demand DOX release, achieving a synergistic photothermal‐chemotherapeutic effect. Notably, both in vitro and in vivo studies reveal that this system effectively induces cancer cell necrosis through a multimodal mechanism: disruption of lysosomes, induction of DNA damage, and simultaneous suppression of heat shock protein (HSP) expression. This integrated strategy results in significantly enhanced therapeutic outcomes, overcoming key limitations of conventional chemotherapy.